Last reviewed · How we verify
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function
This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
Details
| Lead sponsor | Biogen |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | Fri Jul 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hepatic Impairment
Interventions
- Omaveloxolone 50 mg capsules
Countries
United States